Dorothea Elisabeth Meschke

Ms. Dorothea Elisabeth Meschke

orcid

Research Focus & Metrics

Academic Career Length

1Year (2026-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
27 May 2026 in Cancers
Verified
Journal Article
Open access
PDF file
ISIrina Surovtsova
Irina Surovtsova
WEWilfried Ernst Erich Eberhardt
Wilfried Ernst Erich Eberhardt
DMDorothea Elisabeth Meschke
Dorothea Elisabeth Meschke
PMPhilipp Morakis
Philipp Morakis
Background: Checkpoint inhibitors (CPIs) improve the survival in advanced NSCLC and ES-SCLC, but reproducibility of randomized trial results in routine practice remains unclear. Target trial emulation enables approximation of randomized trial designs using observational data while reducing common biases. Methods: Using the Baden-Württemberg Cancer Registry, we emulated four pivotal trials: KEYNOTE-189 (eKN189), KEYNOTE-407 (eKN407), IMpower133 (eIMP133), and PACIFIC (ePACIFIC). The eligibility criteria, treatment strategies, and outcomes were aligned with the original trials as closely as possible within registry constraints. Time-zero was defined as the treatment initiation for systemic therapy cohorts (eKN189, eKN407, eIMP133) and as completion of chemoradiotherapy for ePACIFIC. The treatment groups were balanced using propensity-score-based inverse probability weighting. The outcomes included the overall survival (OS) and the objective response rate (ORR). Results: A total of 4015 patients were included (eKN189: 1762; eKN407: 467; eIMP133: 1190; ePACIFIC: 595). After weighting, the baseline covariates were well balanced. ICI-based regimens were associated with an improved survival: eKN189: HR—0.59 (95% CI: 0.52–0.66), 5-year OS—22.7% vs. 4.7%; eKN407: HR—0.69 (95% CI: 0.54–0.89), 5-year OS—11.8% vs. 6.6%; eIMP133: HR—0.7 (95% CI: 0.62–0.79), 5-year OS—12.8% vs. 5.3%; ePACIFIC: HR—0.51 (95% CI: 0.39–0.66), 5-year OS—47.3% vs. 23.4%. The OS curves demonstrated long-term plateaus across CPI-containing arms. The ORRs were consistently higher with CPI-containing regimens (eKN189: 41.6% vs. 29.6%; eKN407: 44.8% vs. 31.5%; eIMP133: 51.7% vs. 43.1%; ePACIFIC: 56.6% vs. 47.1%). Conclusions: This registry-based target trial emulation reproduced the survival patterns observed in four landmark lung cancer RCTs within trial-like real-world populations, supporting the external validity of pivotal immunotherapy trials while reinforcing the role of high-quality registries as a powerful complement to randomized trials in oncology.